The FDA drug approvals database lists a supplement action dated 15 October 2026 on ANDA 200828, a generic lamotrigine application held by Impax Laboratories. The record does not describe what the supplement changes.
Supplements to generic applications usually concern labelling updates to match the reference product, or manufacturing changes. This should be read as administrative unless the label change itself is published with new safety information.
- No change in prescribing is needed on the strength of this entry.
- Switches between lamotrigine manufacturers can matter to some patients; note the product when seizure control changes.
- Indian supply and labelling are governed by CDSCO.
Why it matters
Generic lamotrigine is widely used, and label changes on generics usually track the reference product.
Don't overread it
A supplement action on a generic application is not a new safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free